Sanofi and Sobi Score US Approval for Weekly Hemophilia A Therapeutic
Altuviiio, Sanofi and Sobi’s therapeutic for the blood disease hemophilia A, has just received regulator approval by the US Food and Drug Administration (FDA). The drug stands out in its class due to its dosage regimen; the therapy is delivered once a week versus every couple days with the current standard of care.
ICER Publishes Final Report on Hemophilia A Therapies
Today the Institute for Clinical and Economic Review (ICER) released a report concluding that compared to common current dosing levels [...]
ICER Publishes Evidence Report on Therapies for Hemophilia A
Today the Institute for Clinical and Economic Review (ICER) released a report concluding that compared to common current dosing levels [...]
ICER finds BioMarin’s Hemophilia Gene Therapy Could Have Warranted a Record Price Tag
Hemophilia is a very expensive disease to treat. Therapies that provide replacement clotting protein are not entirely effective but still [...]
Advertisement
